Suggested remit - To appraise the clinical and cost effectiveness of luspatercept within its marketing authirsation for treating beta-thalassaemia
The company, Celgene UK, has informed NICE that they are unable to provide an evidence submission at this time and will work with us to reschedule. Therefore, we are suspending the appraisal whilst we consider the next steps. Consequently the discussion of this appraisal at the committee meeting on the 8 July 2020 has been cancelled.
 
Status Suspended
Decision Selected
Process STA 2018
ID number 1554

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Stakeholders

Companies sponsors Celgene (luspatercept)
Others Department of Health and Social Care
  NHS Bexley CCG
  NHS England
  NHS West London CCG
  Welsh Government
Patient carer groups Black Health Agency
  Blood Cancer UK
  Equalities National Council
  Genetic Alliance UK
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  UK Thalassaemia Society
Professional groups British Blood Transfusion Society
  British Society for Bone Marrow Transplantation (BSBMT)
  British Committee for Standards in Haematology
  British Society for Haematology
  NHS Blood & Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Forum on Haemoglobin Disorders
  UK Haemophilia Centre Doctors’ Organisation
  UK National Screening Committee
Assessment group Cochrane Haematological Malignancies Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  National Primary Care Research & Development Centre
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Hospira UK (desferrioxamine)
  Novartis Pharmaceuticals (desferrioxamine, deferasirox)
  Swedish Orphan Biovitrum (deferiprone)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
24 January 2020 Suspended. The company, Celgene UK, has informed NICE that they are unable to provide an evidence submission at this time and will work with us to reschedule. Therefore, we are suspending the appraisal whilst we consider the next steps. Consequently the discussion of this appraisal at the committee meeting on the 8 July 2020 has been cancelled.
25 October 2019 Invitation to participate
24 May 2019 - 24 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual